Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease portal hypertension
Comorbidity |cirrhosis
Sentences 135
PubMedID- 24719556 Background: oxidative stress is involved in the hypocontractility of visceral artery to vasoconstrictors and formation of hyperdynamic circulation in cirrhosis with portal hypertension.
PubMedID- 23251280 The patients all suffered from hepatic cirrhosis decompensation with portal hypertension.
PubMedID- 25417057 Lsm of cirrhosis patients with portal hypertension was significantly higher compared to those without portal hypertension (p < 0.05).
PubMedID- 25037870 Hcc patients seemed to suffer from less severe or shorter duration of portal hypertension compared with child-pugh class-matched cirrhosis patients.
PubMedID- 25135728 cirrhosis with portal hypertension is a common disease which has a significant impact on the quality of patients' life.
PubMedID- 25892988 This study aimed to further investigate portal venous remodeling in the pathogenesis of liver cirrhosis with portal hypertension, thereby guiding its prevention and treatment.
PubMedID- 24274743 After feeding for 12 to 24 weeks, these animals may develop cirrhosis with portal hypertension.
PubMedID- 25848469 This review describes the recent developments in the pathobiology of endothelial dysfunction (ed) in the context of cirrhosis with portal hypertension and defines novel strategies and potential targets for therapy.
PubMedID- 22333168 Conclusion: the arb is effective in reducing portal hypertension in patients with cirrhosis, which is similar to propranolol.
PubMedID- 25657603 Progressive cirrhosis, with portal hypertension, is characterized by the development of portosystemic shunts and inadequately cleared circulating vasoactive substances eg, nitric oxide, vasoactive intestinal peptide, endocannabinoids, and bile salts, which create a state of splanchnic and arterial vasodilation, leading to ineffective central blood volume, initially compensated by high cardiac output.3,8 with worsening cirrhosis, systemic vascular resistance continues to fall, but cardiac compensation reaches a maximum.
PubMedID- 24505457 If untreated, ba progresses to cirrhosis, with portal hypertension and liver failure leading to death within two to three years.
PubMedID- 26516439 The american association for the study of liver diseases (aasld) and the european association for the study of the liver (easl) have established guidelines that indicate that liver cirrhosis with portal hypertension is a relative contraindication for hepatic resection because of the high risk liver failure after the operation (14–17).
PubMedID- 20425483 Presentations range from incidentally discovered cirrhosis to complications of advanced portal hypertension and hepatocellular cancer.
PubMedID- 24502094 Results: sixteen patients were found to have liver cirrhosis, three of them with portal hypertension.
PubMedID- 21501480 The obstruction of bile flow results in worsening cholestasis, liver fibrosis, and cirrhosis, which lead to portal hypertension and a decline in hepatic synthetic function.
PubMedID- 24775062 Pathology such as myeloproliferative disorder, liver cirrhosis with portal hypertension, deficiency of natural anticoagulant proteins such as protein c or antithrombin iii as well as hepatocellular carcinoma also could contribute to pvt.
PubMedID- 21699820 Tips has been used to manage the complications of portal hypertension in cirrhosis, including variceal hemorrhage and refractory ascites.
PubMedID- 25053449 Liver collagen in cirrhosis correlates with portal hypertension and liver dysfunction.
PubMedID- 24563796 Relevant diagnoses of the patient were (i) known hypertensive cardiac disease (transthoracic echocardiography 6 months before had shown a lv-ef of 54% and a light mitral and tricuspid insufficiency) and (ii) liver cirrhosis with portal hypertension.
PubMedID- 19918014 We defined liver disease as one of the following: 1) abnormal liver function tests, 2) cirrhosis with portal hypertension, or 3) use of supplementary bile acids.
PubMedID- 20968204 The kidney in cirrhosis with portal hypertension.
PubMedID- 26370856 Hypothyroidism enhanced portal hypertension in a patient with alcoholic liver cirrhosis, resulting in the development of ascites.
PubMedID- 23729979 Portal vein interventions in liver transplant recipients represent a group of interventions in the management of several disease entities including portal vein stenosis, portal vein thrombosis, and recurrent liver cirrhosis with portal hypertension with and without gastric varices.
PubMedID- 20300546 To prevent immediate and late sequelae of hepatolithiasis, such as suppurative cholangitis, septicemia, secondary biliary cirrhosis with resultant portal hypertension, bleeding varices, and hepatic failure [5], aggressive treatment is needed.
PubMedID- 20814511 Surgical intervention in cirrhosis of liver with portal hypertension is associated with increased morbidity and mortality.
PubMedID- 24729881 17 (7%) patients had a mild hepatic comorbidity (score 1) (bilirubin > uln to 1.5 × uln or ast/alt > uln to 2.5 × uln) and 1 patient additional liver cirrhosis with portal hypertension (score 3).
PubMedID- 25543221 Liver cirrhosis with portal hypertension is also associated with the presence of pahs in 1-2% of cases.
PubMedID- 24339715 Severe chronic illness included liver cirrhosis with portal hypertension, new york heart association class iv congestive heart failure, chronic respiratory disease, end-stage renal disease, or an immune-compromised state (e.g., leukemia, lymphoma, or aids).
PubMedID- 20616408 cirrhosis leads to portal hypertension which induces portosystemic collaterals, allowing gut-derived humoral substances to directly enter the systemic circulation without detoxification by the liver.
PubMedID- 24493093 From 2,879 cases that underwent ce, 45 cirrhosis patients with portal hypertension (ph) were enrolled and divided into phe (n = 18) and non-phe (n = 27) groups.
PubMedID- 24940392 In addition, cirrhosis leads to portal hypertension and hyperdynamic circulation that can have widespread effects in the body (15).
PubMedID- 23275766 Upper gastrointestinal hemorrhage is a common complication of hepatic cirrhosis with systemic portal hypertension, while rarely caused by pancreatic diseases.
PubMedID- 24748895 Meanwhile, a clinical trial demonstrated that prophylactic use of ppis did not improve the portal hypertension-related bleeding in patients with cirrhosis (41).
PubMedID- 21785606 Intestinal bacterial overgrowth, seen in patients with advanced cirrhosis as a result of portal hypertension, has been noted to be a prerequisite for the facilitation of bacterial translocation.
PubMedID- 22441510 Conclusion: hscrp is elevated in patients with cirrhosis and is associated with portal hypertension and decreased survival.

Page: 1 2 3